The answer: Because nicotine temporarily addresses the specific neurochemical deficits that many mental illnesses produce, making smoking more reinforcing, more rapid in its dependence formation, and harder to quit in this population than in the general population.
The neurochemical overlap
Most major mental illnesses involve dysregulation of the same neurotransmitter systems that nicotine acts on. They are dopamine, serotonin, norepinephrine, and acetylcholine.
Schizophrenia involves dopamine dysregulation and impaired nicotinic acetylcholine receptor function, as nicotine temporarily improves sensory gating, attention, and cognitive processing in ways that are measurably real for this population. Depression involves serotonin and dopamine deficits that nicotine temporarily addresses. Anxiety involves norepinephrine dysregulation that nicotine transiently modulates. ADHD involves the prefrontal dopamine deficit.
In each case, nicotine is providing real, immediate, neurochemically specific relief from symptoms that are genuinely impairing. The reinforcement is therefore more powerful than in the general population, not because people with mental illness lack willpower, but because the reward nicotine delivers is more neurochemically relevant to their specific deficit state.
The medication interaction
Many psychiatric medications (particularly antipsychotics) are metabolized faster in smokers because tobacco smoke induces liver enzymes that accelerate drug clearance. Smokers on antipsychotics often require higher doses to achieve therapeutic blood levels than non-smokers.
This creates a specific clinical complication at cessation. When smoking stops, enzyme induction reduces, drug metabolism slows, and blood levels of psychiatric medications rise, sometimes to levels that produce adverse effects. This is why informing the prescribing physician before the quit date is clinically essential for anyone on psychiatric medication, not merely recommended.
The institutional and social layer
Smoking rates in psychiatric inpatient settings have historically been extremely high, partly driven by institutional culture where smoking was permitted and socially embedded, partly by staff who used cigarettes as behavioral management tools, and partly by the genuine symptomatic relief smoking provided in environments with limited other pleasures or activities.
People with severe mental illness also face higher rates of social disadvantage, unemployment, and social isolation- all of which are independent risk factors for smoking and barriers to cessation.
Why quitting is harder in this population
Deeper physical dependence from higher smoking rates. More powerful reinforcement from neurochemically relevant relief. Cognitive and motivational impairments from the illness itself that affect cessation planning and follow-through. Medication interactions that require clinical management during cessation. And a mental health system that has historically under-prioritized tobacco cessation for psychiatric patients, sometimes explicitly deprioritizing it as a lower-order concern than the primary diagnosis.
What works
Integrated treatment with cessation support embedded within mental health care rather than offered separately produces significantly better outcomes than cessation support alone. The physician managing the mental health condition needs to be actively involved in the cessation attempt, not informed after the fact.
Varenicline is appropriate for most people with mental illness; the EAGLES trial established this specifically. Bupropion is particularly relevant for depression and may have benefit for schizophrenia. NRT is appropriate across psychiatric diagnoses.
Exercise, structured routine, and behavioral support are more important in this population than in general cessation, compensating for the executive function and motivational deficits that impair self-directed cessation.
The one thing to hold onto
People with mental illness smoke more because nicotine helps, though temporarily, incompletely, at enormous long-term cost.
The goal is not to dismiss the help it provided. It is to find the same neurochemical relief through means that don’t rebuild the deficit they appear to solve and to do it with the clinical support this population specifically requires.
Cignix is India’s neural circuit-based smoking cessation platform. The Cignix Protocol works with the biology of how smoking is learned and how it is unlearned. The entry point is the Smoking Immunity Meter at learn.cignix.com/user/sim. Visit cignix.com.